News | April 15, 2026
Vetter ramps up global clinical manufacturing push with major US & Europe expansion
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Move amid evidence of widespread reporting gaps
Scientists at the forum warned of an increasingly volatile health landscape
Subscribe To Our Newsletter & Stay Updated
